Literature DB >> 3162903

Pharmacokinetics and sputum penetration of enoxacin after twice daily oral dosing for seven days.

B R Dobbs1, L R Gazeley, I A Stewart, I R Edwards.   

Abstract

The ability of enoxacin to penetrate into sputum and its distribution and elimination characteristics after dosing to steady state were determined in six subjects with permanent tracheostomies. At steady state the mean trough level of enoxacin in sputum was 1.75 +/- 0.70 mg/kg (mean +/- S.D.), and the corresponding level in plasma was 1.23 +/- 0.32 mg/l. The mean peak sputum concentration at steady state was 7.12 +/- 4.21 mg/kg with the corresponding level in plasma being 4.54 +/- 1.34 mg/l. The ratio of the mean trough concentration of enoxacin in sputum to that in plasma was 1.42 +/- 0.36, and the ratio of the mean peak concentrations was 1.67 +/- 1.07. The pharmacokinetics of enoxacin in sputum were similar to those in plasma, the only significant difference being between the mean times to reach peak concentration (T-max) which were 2.62 +/- 1.04 and 0.92 +/- 0.44 h in sputum and plasma respectively (P less than 0.01). After reaching steady state, the mean area under the plasma time-concentration curve (AUC) from 0 to 12 h (the dosing interval) was 26.6 +/- 5.9 mg/h/l, and the mean AUC (0-12) for sputum was 40.9 +/- 21.8 mg/h/kg. The mean apparent total clearance was 259.6 +/- 48.8 ml/min and the mean apparent volume of distribution was 169.6 +/- 30.51. Enoxacin exhibits a high degree of penetration into sputum which may prove useful in the treatment of bacterial infections of the respiratory tract.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162903     DOI: 10.1093/jac/21.suppl_b.61

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  3 in total

1.  In vitro activity of tosufloxacin, a new quinolone, against respiratory pathogens derived from cystic fibrosis sputum.

Authors:  A G Arguedas; J C Akaniro; H R Stutman; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 3.  Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections.

Authors:  M J Wood
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.